Keywords: Novo Nordisk, Degludec, Tresiba, Ryzodeg, USa, FDA, Diabetes, Cardiovascular safety

Novo Nordisk says US FDA advisory panel to focus on degludec cardiovascular safety

Article | 26 October 2012

Print This

Denmark-based insulin giant Novo Nordisk (NOV: N) late yesterday announced that the US Food and Drug Administration has published information ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in